JP2022521800A - 皮膚がんを治療するためのｐｄ－１阻害剤の投与 - Google Patents

皮膚がんを治療するためのｐｄ－１阻害剤の投与 Download PDF

Info

Publication number
JP2022521800A
JP2022521800A JP2021550167A JP2021550167A JP2022521800A JP 2022521800 A JP2022521800 A JP 2022521800A JP 2021550167 A JP2021550167 A JP 2021550167A JP 2021550167 A JP2021550167 A JP 2021550167A JP 2022521800 A JP2022521800 A JP 2022521800A
Authority
JP
Japan
Prior art keywords
seq
inhibitor
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021550167A
Other languages
English (en)
Japanese (ja)
Inventor
マシュー・ジー・フュリー
イザレル・ロウィ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022521800A publication Critical patent/JP2022521800A/ja
Priority to JP2024225122A priority Critical patent/JP2025041768A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021550167A 2019-02-28 2020-02-27 皮膚がんを治療するためのｐｄ－１阻害剤の投与 Pending JP2022521800A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024225122A JP2025041768A (ja) 2019-02-28 2024-12-20 皮膚がんを治療するためのｐｄ－１阻害剤の投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811827P 2019-02-28 2019-02-28
US62/811,827 2019-02-28
PCT/US2020/020018 WO2020176699A1 (en) 2019-02-28 2020-02-27 Administration of pd-1 inhibitors for treating skin cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024225122A Division JP2025041768A (ja) 2019-02-28 2024-12-20 皮膚がんを治療するためのｐｄ－１阻害剤の投与

Publications (1)

Publication Number Publication Date
JP2022521800A true JP2022521800A (ja) 2022-04-12

Family

ID=70057261

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021550167A Pending JP2022521800A (ja) 2019-02-28 2020-02-27 皮膚がんを治療するためのｐｄ－１阻害剤の投与
JP2024225122A Pending JP2025041768A (ja) 2019-02-28 2024-12-20 皮膚がんを治療するためのｐｄ－１阻害剤の投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024225122A Pending JP2025041768A (ja) 2019-02-28 2024-12-20 皮膚がんを治療するためのｐｄ－１阻害剤の投与

Country Status (12)

Country Link
US (1) US20220259313A1 (https=)
EP (1) EP3930848A1 (https=)
JP (2) JP2022521800A (https=)
KR (1) KR20210134690A (https=)
CN (1) CN113490529A (https=)
AU (1) AU2020228296B2 (https=)
CA (1) CA3137361A1 (https=)
IL (1) IL285050A (https=)
MA (1) MA55084A (https=)
MX (1) MX2021010228A (https=)
SG (1) SG11202108089SA (https=)
WO (1) WO2020176699A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
LT3394103T (lt) 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
WO2020118208A1 (en) 2018-12-07 2020-06-11 Arizona Board Of Regents On Behalf Of The University Of Arizona A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members
WO2022173931A1 (en) * 2021-02-11 2022-08-18 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor
WO2024186917A2 (en) * 2023-03-06 2024-09-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions for pd-l1 inhibition and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197263A1 (en) * 2016-05-13 2017-11-16 Regeneron Pharmaceuticals, Inc. Methods of treating skin cancer by administering a pd-1 inhibitor
WO2018156494A1 (en) * 2017-02-21 2018-08-30 Regeneron Pharmaceuticals, Inc. Anti-pd-1 antibodies for treatment of lung cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
LT3394103T (lt) * 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
SG11201808626WA (en) 2016-04-07 2018-10-30 Chemocentryx Inc Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197263A1 (en) * 2016-05-13 2017-11-16 Regeneron Pharmaceuticals, Inc. Methods of treating skin cancer by administering a pd-1 inhibitor
WO2018156494A1 (en) * 2017-02-21 2018-08-30 Regeneron Pharmaceuticals, Inc. Anti-pd-1 antibodies for treatment of lung cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies", CLINICALTRIALS.GOV ID NCT02383212, vol. ver. 10: 2017-11-09, JPN6024032571, 9 November 2017 (2017-11-09), ISSN: 0005516594 *
ALEXANDER, M.M. ET AL., N ENGL J MED, vol. 378, no. 19, JPN6024006520, 2018, pages 1789 - 1801, ISSN: 0005516591 *
GAISER, M.R. ET AL., EXPERT REV CLIN PHARMACOL, vol. 11, no. 4, JPN6024006522, 2018, pages 345 - 359, ISSN: 0005516593 *
WEBER, J. ET AL., N ENGL J MED, vol. 377, no. 19, JPN6024006521, 2017, pages 1824 - 1835, ISSN: 0005516592 *

Also Published As

Publication number Publication date
AU2020228296B2 (en) 2025-10-02
SG11202108089SA (en) 2021-08-30
KR20210134690A (ko) 2021-11-10
JP2025041768A (ja) 2025-03-26
US20220259313A1 (en) 2022-08-18
CA3137361A1 (en) 2020-09-03
WO2020176699A1 (en) 2020-09-03
CN113490529A (zh) 2021-10-08
IL285050A (en) 2021-09-30
AU2020228296A1 (en) 2021-10-14
EP3930848A1 (en) 2022-01-05
MA55084A (fr) 2022-01-05
MX2021010228A (es) 2021-10-26

Similar Documents

Publication Publication Date Title
KR102464774B1 (ko) Pd-1 억제제를 투여함으로써 피부암을 치료하는 방법
JP2022078265A (ja) 肺癌の処置のための抗ｐｄ－１抗体
AU2020228296B2 (en) Administration of PD-1 inhibitors for treating skin cancer
JP2022532490A (ja) 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ
JP2025041768A5 (https=)
US20260042841A1 (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
BR112020022642A2 (pt) método para tratar câncer em um indivíduo, e, estojo
JP2022512866A (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
US20250326846A1 (en) Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
IL323023A (en) Combination of PD-1 and LAG-3 inhibitors for improved efficacy in melanoma treatment
CN117042795A (zh) 通过施用pd-1抑制剂治疗免疫抑制或免疫受损患者的癌症的方法
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
JP2021107384A (ja) 部位特異的ｈｅｒ２抗体薬物コンジュゲートを用いた処置
TWI916314B (zh) 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
HK40112560A (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
JP2024507866A (ja) Ｐｄ－１阻害剤を投与することにより肺がんを処置する方法
HK40057287A (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
HK40057287B (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
CN118451108A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241220